Ruxolitinib shows activity against Hodgkin lymphoma but not primary mediastinal large B-cell lymphoma

BACKGROUND: The upregulated expression of the JAK/STAT pathway promotes tumor growth in Hodgkin lymphoma (HL) and primary mediastinal large B-cell lymphoma (PMBCL). Based on the hypothesis that JAK2 is a therapeutic target, we performed a prospective pilot study using ruxolitinib. METHODS: Relapsed...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:BMC Cancer
Hlavní autoři: Kim, Seok Jin, Yoon, Dok Hyun, Kang, Hye Jin, Hong, Jung Yong, Lee, Ho Sup, Oh, Sung Yong, Shin, Ho-Jin, Kong, Jee Hyun, Yi, Jun Ho, Sakamoto, Kana, Ko, Young Hyeh, Huh, Jooryung, Lee, Seung-Sook, Takeuchi, Kengo, Shin, Dong-Yeop, Suh, Cheolwon, Kim, Won Seog
Médium: Artigo
Jazyk:Inglês
Vydáno: BioMed Central 2019
Témata:
Research Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6842512/
https://ncbi.nlm.nih.gov/pubmed/31707975
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-019-6303-z
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky